Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2012

View Archived Issues

Merck & Co. patents new hPDK1 inhibitors

New agents for respiratory and other disorders patented by RespiVert

Treatment duration shortened using combination therapy for HCV

Transgene presents preclinical results for new therapeutic Ad5-based HBV vaccine

Novel arginase inhibitors prepared at Mars

Inhibitors of H-PGDS prove effective for asthma therapy

Novel potassium channel blockers disclosed by Merck & Co.

Scientists at Merck & Co. produce new mGlu5 receptor modulators

Japanese scientists discover novel protein kinase inhibitors

Takeda launches Azilva in Japan

CHMP supports monotherapy indication for Eisai's antiepileptic agent Zonegran

EMA recommends approval for AMPA receptor antagonist Fycompa

Poteligeo injection launched in Japan for adult T-cell leukemia-lymphoma

Shionogi launches injectable oxycodone product in Japan

Meiji Seika Pharma licenses COPD drug rights in Japan

Octreotide tested in patients with severe acute pancreatitis

FDA approves Absorica for severe recalcitrant nodular acne

Kalydeco recommended for E.U. approval

Anti-hepatitis C virus activity observed with raloxifene

European CHMP recommends approval of Jentadueto

Summit commences trial of potential disease-modifying drug for Duchenne muscular dystrophy

Ferring and Kyowa Hakko Kirin to copromote nocturnal enuresis drug in Japan

EMA grants positive opinion to Pfizer's Inlyta for kidney cancer

Pfizer's Xalkori capsules now available in Japan for ALK-positive NSCLC

NICE publishes new guideline regarding prescription of opioids for palliative care

ULISES 008 study misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...